Hallux rigidus treated with adipose-derived mesenchymal stem cells: A case report.

Autor:	Braile A; Department of Medical and Surgical Specialties and Dentistry, University of Campania 'Luigi Vanvitelli', Naples 80138, Italy., Toro G; Department of Medical and Surgical Specialties and Dentistry, University of Campania 'Luigi Vanvitelli', Naples 80138, Italy. giusep.toro@gmail.com., De Cicco A; Department of Medical and Surgical Specialties and Dentistry, University of Campania 'Luigi Vanvitelli', Naples 80138, Italy., Cecere AB; Department of Medical and Surgical Specialties and Dentistry, University of Campania 'Luigi Vanvitelli', Naples 80138, Italy., Zanchini F; Department of Medical and Surgical Specialties and Dentistry, University of Campania 'Luigi Vanvitelli', Naples 80138, Italy., Schiavone Panni A; Department of Medical and Surgical Specialties and Dentistry, University of Campania 'Luigi Vanvitelli', Naples 80138, Italy.
Jazyk:	angličtina
Zdroj:	World journal of orthopedics [World J Orthop] 2021 Jan 18; Vol. 12 (1), pp. 51-55. Date of Electronic Publication: 2021 Jan 18 (Print Publication: 2021).
DOI:	10.5312/wjo.v12.i1.51
Abstrakt:	Background: First metatarsophalangeal joint arthritis (FMTPA), also known as hallux rigidus, is the most frequent degenerative disease of the foot. Diagnosis is made through both clinical and radiological evaluation. Regenerative medicine showed promising results in the treatment of early osteoarthritis. The aim of the present study was to report the results of a case of FMTPA treated with the injection of autologous adipose-derived mesenchymal stem cells. Case Summary: A gentleman of 50 years of age presented with a painful hallux rigidus grade 2 resistant to any previous conservative treatment (including nonsteroidal anti-inflammatory drugs and hyaluronic acid injections). An injection of autologous adipose-derived mesenchymal stem cells into the first metatarsophalangeal joint was performed. No adverse events were reported, and both function and pain scales improved after 9 mo of follow-up. Conclusion: The FMTP joint injection of mesenchymal stem cells improved symptoms and function in our patient with FMTPA at 9 mo of follow-up. Competing Interests: Conflict-of-interest statement: The authors declare that they had no conflict of interest. (©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu